RxDoctor Payments Data

Marie Burke, MD

Ophthalmology · Battle Creek, MINPI 1720468119

Payments from drug & device makers

$1,051in general payments, 2019–2025

Across 37 payments — averaging $28.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$257
  • AbbVie$207
  • Sight Sciences, Inc.$136
  • Alcon$130
  • Novartis$89
  • Biotissue Holdings Inc.$65
  • plus $167 from 7 others

What the payments were for

  • Food & beverage$1,051100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,051 in reported general payments places this provider in the 45th percentile of 674 ophthalmology providers in Michigan.

See all ophthalmology providers in Michigan

Medicare billing

Part B allowed, 2024
$438,601
Medicare patients
1,102
Services billed
3,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine130$183,795
XiidraLifitegrast86$125,854
LumiganBimatoprost87$57,699
Cyclosporine123$50,510
ProlensaBromfenac Sodium131$45,145
XdemvyLotilaner18$34,401
Prednisolone Acetate554$24,719
VyzultaLatanoprostene Bunod36$19,939
Brimonidine Tartrate354$18,517
Latanoprost966$18,281
RhopressaNetarsudil Mesylate21$16,472
Travoprost56$11,401
CombiganBrimonidine Tartrate/Timolol26$10,988
Timolol Maleate430$7,120
SimbrinzaBrinzolamide/Brimonidine Tart21$6,809

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$207$252,483243 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$257$145,793122 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$19$45,145131 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$58$34,40118 claims
AlconSimbrinza$130$6,80921 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 674 ophthalmology providers in Michigan.

Other ophthalmology in Battle Creek

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →